List view / Grid view
Lonza has entered a worldwide, non-exclusive licensing agreement with iPS Academia Japan, Inc. for its induced pluripotent stem cell (iPSC) patent portfolio. By entering this agreement, Lonza demonstrates its commitment to the field of regenerative medicine and reinforces its belief that iPSCs are a key platform technology for the cell…
2 August 2012 | By Teva Pharmaceutical Industries Ltd
Dr. Carlo De Notaristefani appointed as President and CEO of Global Operations, and Mr. Aharon (Arik) Yaari as the Executive VP...
2 August 2012 | By Gilead Sciences, Inc.
Gilead Sciences, Inc., together with Mylan Laboratories, Ranbaxy Laboratories Limited and Strides Arcolab, have entered into agreements...
1 August 2012 | By Bristol-Myers Squibb Company
Administration of study drug suspended...
31 July 2012 | By Pfizer
Pfizer also provides update on Tofacitinib filing in the U.S.
31 July 2012 | By FINN PARTNERS
Statistically significant animal model results indicate PLX cells could improve the lives of people with interstitial lung disease...
31 July 2012 | By FOSS NIRSystems Inc
FOSS NIRSystems is pleased to announce the introduction of the FOSS NIRS™ DS2500 analyzer...
30 July 2012 | By Eli Lilly and Company
Data to explore future treatment possibilities for people with type 1 diabetes...
30 July 2012 | By Novartis
The EC has approved Afinitor®...
30 July 2012 | By Abbott
The European Commission has approved HUMIRA®...
30 July 2012 | By GlaxoSmithKline
GSK announced the results of its initial tender offer for all outstanding shares of HGS...
30 July 2012 | By Bristol-Myers Squibb
Bristol-Myers Squibb and AstraZeneca announced the results of analyses...
27 July 2012 | By Roche
Data will be submitted to health authorities globally...
27 July 2012 | By GlaxoSmithKline
Findings support progression towards registration...
27 July 2012 | By pSivida Corp.
For the treatment of vision impairment associated with chronic diabetic macular edema...
